Investor Relations

To Our Stakeholders

Net Sales and Profits Grew Substantially, Driven Mainly by Strong Overseas Performance

China, EMEA and All Other Geographic Regions Deliver Sales Increases
Sharply Higher Profits, Benefiting from Effects of Higher Sales and Yen Depreciation (Against the U.S. Dollar and the Chinese Yuan)

During the first three months of the fiscal year ending March 31, 2016, the Group achieved increases in net sales, centered on higher sales of instruments and reagents in the hematology field*. Furthermore, profits benefited significantly from the effects of higher sales and the impact of yen depreciation against the U.S. dollar and the Chinese yuan, despite appreciating against the euro. Net sales rose 23.3% year on year, with operating income up 28.8%, ordinary income up 32.8% and profit attributable to owners of the parent up 44.7%. At the exchange rates prevailing one year earlier, net sales would have been up 15.0% and operating income up 4.6%.
In Japan, sales in the hematology and immunochemistry fields grew, resulting in an increase. Overseas, sales were particularly robust in China and EMEA, with sales rising in all geographic regions on a local currency basis. Particularly in China, sales of instruments were up, notably in the hemostasis field, and reagent sales grew thanks to an expansion of the installed instrument base. As a result, sales in China surged 44.3% year on year. These factors drove the Sysmex Group’s overseas sales ratio to 86.5%.
We maintain unchanged the consolidated performance forecast we announced in May 2015 for the full fiscal year ending March 31, 2016.
To meet anticipated increases in demand for reagents in the EMEA region, we expanded our reagent factory in Germany. This was part of our efforts to reinforce our global reagent supply structure, following on from 2012 expansions at reagent factories in China and the city of Ono, Hyogo Prefecture, and our Singapore reagent factory in 2014. By building our manufacturing structure to match the market environment and growth in regions around the world, we are working to ensure the stable provision of products to customers globally.

* Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.

Hisashi Ietsugu
Chairman and CEO


Related Links
 - Presentation
 - Financial Data
 - Financial Statement


President and CEO Hisashi Ietsugu
Aug. 2015 
Hisashi Ietsugu
Chairman and CEO
Hisashi Ietsugu

Top of Investor Relation

Sysmex Corporation

Copyright© SYSMEX CORPORATION, All Rights Reserved.